
PIANOFORTE travel grant activity report

Fernando M. Costa, ULS São João, Portugal

Proffered Paper #2916 and Digital Poster #2785 at ESTRO26

The annual congress of the European Society for Radiotherapy and Oncology (ESTRO) is one of the leading international events in the field of radiation oncology, gathering clinicians, medical physicists, radiation therapists, researchers, and industry representatives from around the world. ESTRO26 featured a comprehensive scientific programme including oral communications, poster discussions, digital posters, educational sessions, and networking opportunities focused on the latest developments in radiotherapy and oncology research.

During the congress, I had the opportunity to present two scientific contributions. The first, titled “**Comparative Dosimetric Analysis of SRS VMAT and HyperArc for Single and Multiple Brain Metastases**” (Proffered Paper #2916), was presented as an oral communication. This work focused on the dosimetric comparison between stereotactic radiosurgery VMAT and HyperArc techniques for the treatment of single and multiple brain metastases, highlighting differences in plan quality and treatment delivery characteristics.

The second contribution, titled “**Is There a Gold-Standard Radiotherapy Technique for Early-Stage Left-Sided Breast Cancer – A Systematic Review of Planning Dose Assessment**” (Digital Poster #2785), was presented as a digital poster. This systematic review evaluated and compared different radiotherapy planning techniques for early-stage left-sided breast cancer, exploring dosimetric outcomes and discussing the ongoing search for an optimal treatment approach that maximizes target coverage while minimizing dose to organs at risk.

ESTRO26 also provided an excellent opportunity to engage with colleagues from different institutions, exchange scientific experiences, and discuss emerging technologies and methodologies in radiation oncology. The congress exhibition showcased state-of-the-art radiotherapy equipment, software solutions, and innovations that continue to improve precision and patient care in clinical practice.

Overall, participation in ESTRO26 was an enriching scientific and professional experience, allowing me to disseminate ongoing research, receive valuable feedback from the international community, and strengthen collaborative and networking opportunities within the field of radiation oncology.